Inotuzumab ozogamicin in the treatment of patients with R/R ALL and extramedullary disease
Cristina Papayannidis • 16 Dec 2021
Patients with CLL and partial response to venetoclax-obinutuzumab
Othman Al-Sawaf • 12 Jun 2020
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.